Free Alerts   Login
Health Care › Pharmaceutical Preparations

AGE Stock Price Correlated With AgeX Therapeutics Financials

AGE Stock Price vs. Quarterly
Income Statement
Cash Flow
Balance Sheet

AGE Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

AGE Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

AGE Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Value (x$1000)
increase or decrease
Vanguard Group
698,414 sh
-1,450 sh
Prescott General Partners
185,185 sh
Bridgeway Capital Management
169,770 sh
Geode Capital Management
97,764 sh
-1,847 sh
Strategic Wealth Designers
86,026 sh
-414 sh
Creative Planning
72,360 sh
Summit X
32,500 sh
-500 sh
31,533 sh
Susquehanna International Group,
30,596 sh
-21,785 sh
State Street
26,801 sh
Beirne Wealth Consulting Services
18,000 sh
Tower Research Capital (Trc)
13,525 sh
1,375 sh
Citadel Advisors
13,421 sh
13,421 sh
Lpl Financial
12,893 sh
Riggs Asset Managment Co..
1,060 sh
Piscataqua Savings Bank
1,000 sh
Advisory Services Network
550 sh
Morgan Stanley
486 sh
41 sh
Albion Financial Group
304 sh
Pacifica Partners.
292 sh
Organization, Basis of Presentation and Liquidity

Therapeutics, Inc. (“AgeX”) was incorporated in January 2017 in the state of Delaware as a subsidiary of Lineage Cell Therapeutics,
Inc. (“Lineage,” formerly known as BioTime, Inc.), a publicly traded, clinical-stage biotechnology company.

is a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging and degenerative
diseases. AgeX’s mission is to apply its comprehensive experience in fundamental biological processes of human aging to a broad
range of age-associated medical conditions.

proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows AgeX to utilize telomerase-expressing
regenerative pluripotant stem cells (“PSCs”) for the manufacture of cell-based therapies to regenerate tissues afflicted
with age-related chronic degenerative disease. AgeX’s main technology platforms and product candidates are:

● PureStem ®
PSC-derived clonal embryonic progenitor cell lines that may be capable of generating
a broad range of cell types for use in cell-based therapies;

● UniverCyte™
which uses the HLA-G gene to suppress rejection of transplanted cells and tissues to confer
low immune observability to cells;

using adipose brown fat cells for metabolic diseases such as Type II diabetes and obesity;

using vascular progenitor cells to treat tissue ischemia such as in peripheral vascular disease
and ischemic heart disease; and

● Induced
tissue regeneration or iTR technology to regenerate or rejuvenate cells to treat a variety
of degenerative diseases including those associated with aging, as well as other potential
tissue regeneration applications such as scarless wound repair.

is an “emerging growth company” as defined in the Jumpstart our Business Startups Act of 2012.

sale of significant ownership interest in AgeX to Juvenescence

August 30, 2018, Lineage consummated the sale of 14,400,000
shares of common stock of AgeX owned by Lineage
to Juvenescence Limited (“Juvenescence”). Prior to the transaction, Juvenescence owned 5.6 %
of AgeX’s issued and outstanding common stock. Upon completion of the transaction, Lineage’s ownership in AgeX was reduced
from 80.4 %
to 40.2 %
of AgeX’s issued and outstanding shares of common stock, and Juvenescence’s ownership in AgeX was increased from 5.6 %
to 45.8 %
of AgeX’s issued and outstanding shares of common stock. AgeX did not receive any proceeds from the transaction. As a result of
that transaction, AgeX ceased to be a subsidiary of Lineage because Lineage experienced a “loss of control” of a subsidiary,
as defined by U.S. GAAP. Loss of control is deemed
to have occurred when, among other things, a parent company owns less than a majority of the outstanding common stock in the subsidiary,
lacks a controlling financial interest in the subsidiary and, is unable to unilaterally control the subsidiary through other means such
as having, or being able to obtain, the power to elect a majority of the subsidiary’s Board of Directors based solely on contractual
rights or ownership of shares holding a majority of the voting power of the subsidiary’s voting securities. All of these loss-of-control
factors were present with respect to Lineage’s ownership interest in AgeX as of August 30, 2018. Accordingly, Lineage deconsolidated
AgeX’s consolidated financial statements and results from its consolidated financial statements and results beginning on August
30, 2018.

November 28, 2018 (the “Dis

Free historical financial statements for AgeX Therapeutics Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 17 quarters since 2019. Compare with AGE stock chart to see long term trends.

Data imported from AgeX Therapeutics Inc. SEC filings. Check original filings before making any investment decision.